Next Acadia quarterly has been flagged as limiting downside more than anything. Their Senior Execs have continually been pushing that it will be lower than Q4 24 due to seasonality, sales pull through from this quarter into last and some Medicare changes. I don't know what they'll hit but it's the second half of 2025 that Acadia is highlighting as when they want to see genuine sales growth driven by increased patient numbers. I think the biggest near-term catalysts have to be coming from Neuren with the Ph3 meeting and new indications.
Ann: Update - Notification of buy-back - NEU, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.96 |
Change
-0.140(1.07%) |
Mkt cap ! $1.612B | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.36 | $12.82 | $4.627M | 354.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7585 | $12.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.03 | 3344 | 2 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |